Cullinan Therapeutics (CGEM) Share-based Compensation (2020 - 2026)

Cullinan Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $7.6 million for Q1 2026.

• In Q1 2026, Share-based Compensation fell 18.75% year-over-year to $7.6 million; the TTM figure through Mar 2026 stood at $34.3 million (down 12.03% YoY), while the FY2025 annual figure was $36.1 million, down 29.77% from the prior year.
• Share-based Compensation for Q1 2026 stood at $7.6 million, up from $7.3 million in the prior quarter.
• The five-year high for Share-based Compensation was $10.5 million in Q2 2024, with the low at $5.3 million in Q3 2022.
• The 5-year median for Share-based Compensation is $7.9 million (2023), against an average of $8.2 million.
• Peak annual rise in Share-based Compensation reached 106.67% in 2022, while the deepest fall reached 38.14% in 2022.
• Cullinan Therapeutics' Share-based Compensation stood at $7.5 million in 2022, then rose by 0.08% to $7.5 million in 2023, then rose by 28.13% to $9.6 million in 2024, then dropped by 24.1% to $7.3 million in 2025, then climbed by 4.16% to $7.6 million in 2026.
• Business Quant data shows CGEM's Share-based Compensation at $7.6 million in Q1 2026, $7.3 million in Q4 2025, and $9.5 million in Q3 2025.